AcquisitionOther
Aeglea BioTherapeutics, Inc. acquired Spyre
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Aeglea BioTherapeutics, Inc. -> Spyre · $15 million
Immedica has made substantial progress in working towards a European market approval.
Open source record (SEC) ↗